<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(6)</volume><submitter>Xu C</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Primary liver cancer (PLC) is a leading cause of cancer-related mortality, with many patients ineligible for curative resection. Transcatheter arterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) are two key interventional therapies recommended for unresectable cases. Recent studies suggest that combining them may enhance treatment efficacy compared to either approach alone. This prospective study aims to evaluate the safety and efficacy of TACE combined with HAIC in patients with unresectable PLC.&lt;h4>Methods&lt;/h4>Patients with unresectable primary hepatocellular carcinoma (China Liver Cancer stage IIa-III, without distant metastasis) who received TACE combined with HAIC from February 2023 to September 2024, at the Department of Intervention</pubmed_abstract><journal>Journal of gastrointestinal oncology</journal><pagination>2731-2740</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12780682</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Safety and efficacy of transcatheter chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable primary liver cancer: a single-center prospective study.</pubmed_title><pmcid>PMC12780682</pmcid><pubmed_authors>Pan J</pubmed_authors><pubmed_authors>Lu Y</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Sun J</pubmed_authors><pubmed_authors>Liang Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>Safety and efficacy of transcatheter chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable primary liver cancer: a single-center prospective study.</name><description>&lt;h4>Background&lt;/h4>Primary liver cancer (PLC) is a leading cause of cancer-related mortality, with many patients ineligible for curative resection. Transcatheter arterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) are two key interventional therapies recommended for unresectable cases. Recent studies suggest that combining them may enhance treatment efficacy compared to either approach alone. This prospective study aims to evaluate the safety and efficacy of TACE combined with HAIC in patients with unresectable PLC.&lt;h4>Methods&lt;/h4>Patients with unresectable primary hepatocellular carcinoma (China Liver Cancer stage IIa-III, without distant metastasis) who received TACE combined with HAIC from February 2023 to September 2024, at the Department of Intervention</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T12:43:14.2Z</modification><creation>2026-05-30T03:11:17.891Z</creation></dates><accession>S-EPMC12780682</accession><cross_references><pubmed>41522752</pubmed><doi>10.21037/jgo-2025-459</doi></cross_references></HashMap>